Factors associated with COVID-19 among hospitalized patients with severe acute respiratory infections in Serbia, 2022–2023: A test negative case-control study

Author:

Stosic MajaORCID,Plavsa Dragana,Jovanovic Verica,Veljkovic Marko,Babic Dragan,Knezevic AleksandraORCID,Saponjic Vladan,Dimitrijevic Dragana,Rancic Miljan,Milic Marija,Adzic-Vukicevic Tatjana

Abstract

Severe acute respiratory infections (SARI) are estimated to be the cause of death in about 19% of all children younger than 5 years globally. The outbreak of coronaviral disease (COVID-19) caused by SARS-CoV-2, increased considerably the burden of SARI worldwide. We used data from a vaccine effectiveness study to identify the factors associated with SARS CoV-2 infection among hospitalized SARI patients. We recruited SARI patients at 3 hospitals in Serbia from 7 April 2022–1 May 2023. We collected demographic and clinical data from patients using a structured questionnaire, and all SARI patients were tested for SARS-CoV-2 by RT-PCR. We conducted an unmatched test negative case-control study. SARS-CoV-2 infected SARI patients were considered cases, while SARS CoV-2 negative SARI patients were controls. We conducted bivariate and multivariable logistic regression analysis in order to identify variables associated with SARS-CoV-2 infection. We included 110 SARI patients: 74 were cases and 36 controls. We identified 5 factors associated with SARS-CoV-2 positivity, age (OR  =  1.04; 95% CI  =  1.01–1.07), having received primary COVID-19 vaccine series (OR  =  0.28; 95% CI  =  0.09–0.88), current smoking (OR  =  8.64; 95% CI  =  2.43–30.72), previous SARS CoV-2 infection (OR  =  3.48; 95% CI  =  1.50–8.11) and number of days before seeking medical help (OR  =  0.81; 95% CI  =  0.64–1.02). In Serbia during a period of Omicron circulation, we found that older age, unvaccinated, hospitalized SARI patients, previously infected with SARS CoV-2 virus and those who smoked, were more likely to be SARS-CoV-2-positive; these patient populations should be prioritized for COVID vaccination.

Publisher

Public Library of Science (PLoS)

Reference39 articles.

1. World Health Organization. World Health Organization Global Epidemiological Surveillance Standards for Influenza. Accessed July 26, 2023. https://www.who.int/publications/i/item/9789241506601.2013

2. WHO. Acute respiratory infections: the forgotten pandemic. Accessed July 26, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2305630/pdf/bullwho00001-0104.pdf

3. Operational considerations for influenza surveillance in the WHO European Region during COVID-19: interim guidance. https://www.ecdc.europa.eu/sites/default/files/documents/Joint-influenza-interim-guidance.pdf

4. Methodological Guidelines for Surveillance of Influenza in Serbia. Institute of Public Health of Serbia „Dr Milan Jovanovic Batut“, available at: https://www.batut.org.rs/download/aktuelno/grip/SMU%2020122013.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3